Top-News

Northwest Biotherapeutics Aktie News

Aktie
WKN:  A1J5EY ISIN:  US66737P6007 US-Symbol:  NWBO Branche:  Biotechnologie Land:  USA
0,232 $
-0,0016 $
-0,67%
0,19925 € 21:59:53 Uhr
Depot/Watchlist
Marktkapitalisierung *
296,73 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Northwest Biotherapeutics News

20.11.25 - PR Newswire
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility PR Newswire
20.11.25 - PR Newswire
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility PR Newswire
24.10.25 - PR Newswire
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed PR Newswire
24.10.25 - PR Newswire
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed PR Newswire
27.08.25 - PR Newswire
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd. PR Newswire
27.08.25 - PR Newswire
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd. PR Newswire
18.08.25 - PR Newswire
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman PR Newswire
18.08.25 - PR Newswire
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman PR Newswire
11.06.25 - PR Newswire
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-​Tumor Treatments PR Newswire
11.06.25 - PR Newswire
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-​Tumor Treatments PR Newswire
26.12.24 - PR Newswire
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing PR Newswire
26.12.24 - PR Newswire
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing PR Newswire
03.07.24 - PR Newswire
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities PR Newswire
03.07.24 - PR Newswire
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities PR Newswire
17.06.24 - PR Newswire
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
Northwest Biotherapeutics Announces Exclusive In-​License of Portfolio of Dendritic Cell Technology and Intellectual Property PR Newswire
17.06.24 - PR Newswire
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
Northwest Biotherapeutics Announces Exclusive In-​License of Portfolio of Dendritic Cell Technology and Intellectual Property PR Newswire
21.03.24 - PR Newswire
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors PR Newswire
06.02.24 - PR Newswire
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-​Compliant Units For Installation, Validation and Final Testing Prior to Regulatory ...
21.12.23 - PR Newswire
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma PR Newswire
21.12.23 - PR Newswire
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »